Promising Lilly cancer drug fails in disappointing trial, shares fall 3 percent
Analysts had predicted that Lartruvo could eventually ring up as much as $600 million in annual sales. Eli Lilly and Co. now says it will suspend promotion of the drug.
Eli Lilly and Co.
Articles
Lilly wins national award for advancing women in the workplace
The Catalyst Award recognizes companies that excel in addressing recruitment, development and advancement of women. Today, nearly half of Lilly's senior leadership is female, up from 20 percent four years ago.
Would-be dealmakers warn of M&A, IPO delays due to shutdown
A prolonged shutdown could muddle Eli Lilly and Co.’s plan to unload its stake in Elanco Animal Health Inc., the unit it spun off last year, Lilly CEO Dave Ricks said.
Lilly to disclose more information about drug pricing
Eli Lilly and Co. won’t put the price of its prescription drugs in television ads, as the Trump administration has called for pharmaceutical companies to do, but will begin promoting a website where prices are available.
Lilly execs: $8B acquisition feeds into cancer drug strategy
Drug industry analysts on Monday applauded Eli Lilly and Co.’s pending $8 billion cash deal to buy a startup that focuses on oncology, which has become a prime focus for the pharma giant in the last year.
In its biggest takeover ever, Lilly buying cancer drug startup for $8 billion
Connecticut-based Loxo Oncology, which was founded in 2013 and went public a year later, has a cancer drug in development that recently received U.S. Food and Drug Administration "breakthrough therapy" status.
Big pharma stocks among top performers in 2018
Pharmaceutical giants Merck & Co. and Pfizer Inc. were kings of the Dow Jones industrial index during the year, while Eli Lilly and Co. was among the 20 largest gainers on the S&P 500.
Trump Medicare plan targets drugs from Eli Lilly, others
Makers of antidepressants and antipsychotics like Indianapolis-based Eli Lilly and Co., AstraZeneca, Pfizer, Allergan, Bausch Health and Otsuka Holdings might face new challenges and may be deterred from price hikes.
Rising fear among Asians leads Eli Lilly to rethink employee groups
New employees at Eli Lilly and Co. get a letter encouraging them to join one of the pharmaceutical firm’s affinity groups. There’s one for African Americans, one for Latino employees—and four for Asians.
Eli Lilly considering sale of China assets to raise cash
Indianapolis-based Lilly is working with advisers to gauge interest in selling off a selection of older drugs for antibiotics and central nervous system diseases in China.
Janitor uprising highlights tensions over outsourcing
Nearly 650 Indianapolis-area janitors represented by the Service Employees International Union work for just eight firms that clean downtown office buildings.
Lilly raises guidance after topping profit, revenue expectations
Lilly’s revenue in the United States rose 11 percent year-over-year, to $3.4 billion, thanks largely to rising sales of diabetes drugs Trulicity and Basgalar, cancer treatment Verzenio and psoriasis medication Taltz.
Eli Lilly partner urges investors to look beyond biotech turmoil
Look at the future prospects, not the losses, says the CEO of a newly listed Chinese biotech company that’s developing anti-cancer drugs with Indianapolis-based Eli Lilly and Co.
Police remove dozens of demonstrators in janitors’ protest
Nearly 50 demonstrators, including Democratic City-County Council members Zach Adamson and Duke Oliver, were issued written summons Thursday for violating a city ordinance and not complying with police.
Trump focusing on drug prices, high among voters’ concerns
President Donald Trump is linking the drug prices Americans complain about to one of his longstanding grievances: foreign countries the president says are taking advantage of U.S. research breakthroughs.
Opioid alternative from Lilly, Pfizer shows promise in study
The experimental drug eased arthritis pain in hard-to-treat patients without major safety concerns, a key step in creating a new class of medications that may one day offer an alternative to narcotics.
Lilly might market diabetes drug for obesity after research results
Eli Lilly and Co.’s stock jumped Thursday after midstage research on an experimental diabetes drug showed significant weight loss in patients. The news took a toll on shares of rival Novo Nordisk.
Big gymnasium in downtown corporate campus to be demolished
The owner of the 40,000-square-foot gym says upgrading the facility would cost tens of millions of dollars, and that the cost to maintain it is greater than the property’s value.
Lilly’s Elanco animal-health business raises $1.5 billion in IPO
Greenfield-based Elanco Animal Health Inc. raised more than expected in its initial public offering, pricing its shares above the marketed price range.
Competitor beats Lilly to market with migraine drug approval
The competition for the multi-billion dollar migraine market is set to heat up with the FDA expected to decide on Lilly’s migraine therapy next month.